BEAM
Beam Therapeutics Inc
NASDAQ · Biotechnology
$26.52
+1.79 (+7.24%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 78.31M | 73.18M | 539.73M | 476.44M | 432.89M |
| Net Income | -464,440,668 | -390,614,523 | -53,413,528 | -46,993,180 | -41,441,136 |
| EPS | — | — | — | — | — |
| Profit Margin | -593.1% | -563.5% | -9.9% | -9.9% | -9.6% |
| Rev Growth | +7.0% | +7.0% | -3.6% | -6.6% | +15.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 351.97M | 420.07M | 396.17M |
| Total Equity | — | — | 2.02B | 1.92B | 2.06B |
| D/E Ratio | — | — | 0.17 | 0.22 | 0.19 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -483,315,008 | -429,071,355 | -41,391,154 | -41,088,618 | -32,500,848 |
| Free Cash Flow | — | — | -43,209,591 | -33,034,013 | -43,893,077 |